Los Angeles Capital Management
OVID icon

Los Angeles Capital Management’s Ovid Therapeutics OVID Stock Holding History

Los Angeles Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,681
Closed -$4.89K – 1428
2025
Q1 		$4.89K Buy
+15,681
New +$9.64K ﹤0.01% 1077
2021
Q3 		– Sell
-28,360
Closed -$111K – 1562
2021
Q2 		$111K Sell
28,360
-4,500
-14% -$17.8K ﹤0.01% 1511
2021
Q1 		$132K Sell
32,860
-41,510
-56% -$138K ﹤0.01% 1562
2020
Q4 		$172K Buy
74,370
+3,170
+4% +$14.8K ﹤0.01% 1483
2020
Q3 		$409K Sell
71,200
-8,980
-11% -$60.1K ﹤0.01% 1163
2020
Q2 		$591K Buy
+80,180
New +$375K ﹤0.01% 1046

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Los Angeles Capital Management's OVID Position: Q2 2025 in Review

Los Angeles Capital Management sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 15,681 shares — an estimated $4.89K sold.

Los Angeles Capital Management first reported a position in OVID in Q2 2020 and held it in 6 quarters. The position peaked at $591K in Q2 2020. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Los Angeles Capital Management reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 15,681 Ovid Therapeutics shares in Q2 2025, an estimated $4.89K.
  • Los Angeles Capital Management first reported a position in Ovid Therapeutics in Q2 2020 and held it in 6 quarters.
  • Los Angeles Capital Management's Ovid Therapeutics position peaked at $591K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Los Angeles Capital Management's 13F filing for Q2 2025, filed 7 Aug 2025.